(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2020 (15.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/210722 A1

(51) International Patent Classification:
A61K 38/00 (2006.01) *A61K 47/14* (2017.01)
A61K 9/08 (2006.01) *A61K 31/4545* (2006.01)
A61K 9/10 (2006.01)

(21) International Application Number:
PCT/US2020/027800

(22) International Filing Date:
10 April 2020 (10.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/832,508 11 April 2019 (11.04.2019) US

(71) Applicants: **R.P. SCHERER TECHNOLOGIES, LLC** [US/US]; 112 North Curry Street, Carson City, Nevada 89703 (US). **BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.** [US/US]; 215 Church Street, New Haven, Connecticut 06510 (US).


(72) Inventors: **PLASSAT, Vincent**; 9 rue de l'Orme aux Loups, 91590 La Ferté Alais (FR). **HILBOLD, Benoit**; 26 rue de Saales, 67300 Schiltigheim (FR). **GALUS, Aurélia**; 138 rue de la République, 67720 Weyersheim (FR). **POINTEAUX, Thomas**; 7 rue des Tulipes, 67116 Reichstett (FR). **MEISSONNIER, Julien**; 4 rue Saint Nabor, 67460 Souffelweyersheim (FR). **DUBOWCHIK, Gene M.**; c/o Biohaven Pharmaceutical Holding Company Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **CONWAY, Charles M.**; c/o Biohaven Pharmaceutical Holding Company Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **VOGLER, Nathan** et al.; Morrison & Foerster LLP, 1650 Tysons Boulevard, Suite 300, McLean, Virginia 22102-4220 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY

FIG. 1



(57) Abstract: The present disclosure is directed to a pharmaceutical formulation intended for oral delivery of synthetic or natural poorly permeable calcitonin gene-related peptide (CGRP) inhibitors or salts/solvates thereof having a therapeutic activity. The pharmaceutical formulation can include a synthetic or natural poorly permeable CGRP inhibitors or salt or solvate thereof in an amount 0.01-10 wt. % of the total weight of the formulation; a lipophilic phase comprising triglycerides of fatty acids in an amount of 50-80 wt.% of the total weight of the formulation; and at least one lipophilic surfactant comprising partial esters of polyol and fatty acids in an amount of about 10-50 wt.% of the total weight of the formulation.

WO 2020/210722 A1

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*